Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes

Nature Communications

Volumn 8, Issue 1, 2017, Pages

  Zhu, Jingjing ^a,b,c   Powis De Tenbossche, Céline G ^a,b   Cané, Stefania ^a,b,c   Colau, Didier ^a,b   Van Baren, Nicolas ^a,b   Lurquin, Christophe ^a,b   Schmitt Verhulst, Anne Marie ^d   Liljeström, Peter ^e   Uyttenhove, Catherine ^a,b   Van Den Eynde, Benoit J ^a,b,c  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^b DE DUVE INSTITUTE   (Belgium)

^c Walloon Excellence in Life Sciences and Biotechnology   (Belgium)

^d CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND; TAMOXIFEN; CANCER VACCINE; FAS PROTEIN, MOUSE; FASL PROTEIN, MOUSE; FASLG PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 6;

APOPTOSIS; CANCER; CELLS AND CELL COMPONENTS; DISEASE RESISTANCE; DISEASE TREATMENT; IMMUNE RESPONSE; INFILTRATION; TUMOR;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ADVERSE OUTCOME; ANIMAL MODEL; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER GRAFT; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL DEATH; CONTROLLED STUDY; FUNCTIONAL STATUS; GENE EXPRESSION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; LYMPH NODE; MOUSE; MYELOID-DERIVED SUPPRESSOR CELL; NONHUMAN; RENAL CELL CARCINOMA; SPLEEN; THERAPY EFFECT; TUMOR ASSOCIATED LEUKOCYTE; UVEA MELANOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; EXPERIMENTAL MELANOMA; FEMALE; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; MALE; PATHOLOGY; PROCEDURES; TRANSGENIC MOUSE; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

ANIMALS; APOPTOSIS; CANCER VACCINES; CELL LINE, TUMOR; FAS LIGAND PROTEIN; FAS RECEPTOR; FEMALE; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, TRANSGENIC; TUMOR MICROENVIRONMENT;

EID: 85034071655     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-017-00784-1     Document Type: Article

References (55)

1. Coulie, P. G., Van den Eynde, B. J., van der Bruggen, P. & Boon, T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat. Rev. Cancer 14, 135-146 (2014).
2. Huijbers, I. J. et al. An inducible mouse model of melanoma expressing a defined tumor antigen. Cancer Res. 66, 3278-3286 (2006).
3. Wehbe, M. et al. Epithelial-mesenchymal-transition-like and TGFbeta pathways associated with autochthonous inflammatory melanoma development in mice. PLoS ONE 7, e49419 (2012).
4. Soudja, S. M. et al. Tumor-initiated inflammation overrides protective adaptive immunity in an induced melanoma model in mice. Cancer Res. 70, 3515-3525 (2010).
5. Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35-44 (2016).
6. Naslund, T. I. et al. Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor. J. Immunol. 178, 6761-6769 (2007).
7. Lurquin, C. et al. Structure of the gene coding for tum-transplantation antigen P91A. A peptide encoded by the mutated exon is recognized with Ld by cytolytic T cells. Cell 58, 293-303 (1989).
8. Willimsky, G. et al. Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. J. Exp. Med. 205, 1687-1700 (2008).
9. Willimsky, G. & Blankenstein, T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437, 141-146 (2005).
10. Shanker, A. et al. Thymocyte-intrinsic genetic factors influence CD8 T cell lineage commitment and affect selection of a tumor-reactive TCR. J. Immunol. 172, 5069-5077 (2004).
11. Griffin, R. J. et al. Use of a fluorescently labeled poly-caspase inhibitor for in vivo detection of apoptosis related to vascular-targeting agent arsenic trioxide for cancer therapy. Technol. Cancer Res. Treat. 6, 651-654 (2007).
12. Spranger, S. et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci. Transl. Med. 5, 200ra116 (2013).
13. Chen, J. et al. Interferon-gamma-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway. Immunobiology 217, 385-393 (2012).
14. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012).
15. van Baren, N. & Van den Eynde, B. J. Tumoral immune resistance mediated by enzymes that degrade tryptophan. Cancer Immunol. Res. 3, 978-985 (2015).
16. Keir, M. E., Butte, M. J., Freeman, G. J. & Sharpe, A. H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677-704 (2008).
17. Xu, X., Fu, X. Y., Plate, J. & Chong, A. S. IFN-gamma induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for upregulation of Fas and FasL expression. Cancer Res. 58, 2832-2837 (1998).
18. Bertrand, F. et al. Blocking tumor necrosis factor alpha enhances CD8 T-celldependent immunity in experimental melanoma. Cancer Res. 75, 2619-2628 (2015).
19. Gabrilovich, D. I., Ostrand-Rosenberg, S. & Bronte, V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253-268 (2012).
20. Youn, J. I. & Gabrilovich, D. I. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur. J. Immunol. 40, 2969-2975 (2010).
21. Chun, E. et al. CCL2 promotes colorectal carcinogenesis by enhancing polymorphonuclear myeloid-derived suppressor cell population and function. Cell Rep. 12, 244-257 (2015).
22. Rodriguez, P. C. et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 69, 1553-1560 (2009).
23. Youn, J. I., Collazo, M., Shalova, I. N., Biswas, S. K. & Gabrilovich, D. I. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J. Leukoc. Biol. 91, 167-181 (2012).
24. Stromnes, I. M., Greenberg, P. D. & Hingorani, S. R. Molecular pathways: myeloid complicity in cancer. Clin. Cancer Res. 20, 5157-5170 (2014).
25. Viola, A., Sarukhan, A., Bronte, V. & Molon, B. The pros and cons of chemokines in tumor immunology. Trends Immunol. 33, 496-504 (2012).
26. Kumar, V., Patel, S., Tcyganov, E. & Gabrilovich, D. I. The nature of myeloidderived suppressor cells in the tumor microenvironment. Trends Immunol. 37, 208-220 (2016).
27. Youn, J. I. et al. Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat. Immunol. 14, 211-220 (2013).
28. Waring, P. & Mullbacher, A. Cell death induced by the Fas/Fas ligand pathway and its role in pathology. Immunol. Cell Biol. 77, 312-317 (1999).
29. Maher, S., Toomey, D., Condron, C. & Bouchier-Hayes, D. Activation-induced cell death: the controversial role of fas and fas ligand in immune privilege and tumour counterattack. Immunol. Cell Biol. 80, 131-137 (2002).
30. de la Cruz, P. O. Jr., Specht, C. S. & McLean, I. W. Lymphocytic infiltration in uveal malignant melanoma. Cancer 65, 112-115 (1990).
31. Whelchel, J. C., Farah, S. E., McLean, I. W. & Burnier, M. N. Immunohistochemistry of infiltrating lymphocytes in uveal malignant melanoma. Invest. Ophthalmol. Vis. Sci. 34, 2603-2606 (1993).
32. Webster, W. S. et al. Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival. Cancer 107, 46-53 (2006).
33. Hahne, M. et al. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 274, 1363-1366 (1996).
34. Seino, K., Kayagaki, N., Okumura, K. & Yagita, H. Antitumor effect of locally produced CD95 ligand. Nat. Med. 3, 165-170 (1997).
35. Arai, H.,Gordon,D.,Nabel, E.G.&Nabel, G. J.Gene transfer of Fas ligand induces tumor regression in vivo. Proc. Natl Acad. Sci. USA 94, 13862-13867 (1997).
36. Restifo, N. P. Not so Fas: re-evaluating the mechanisms of immune privilege and tumor escape. Nat. Med. 6, 493-495 (2000).
37. Alderson, M. R. et al. Fas ligand mediates activation-induced cell death in human T lymphocytes. J. Exp. Med. 181, 71-77 (1995).
38. LA, O. R. et al. Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature 461, 659-663 (2009).
39. Ryan, A. E., Shanahan, F., O'Connell, J. & Houston, A. M. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo. Cancer Res. 65, 9817-9823 (2005).
40. Motz, G. T. et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat. Med. 20, 607-615 (2014).
41. Klebanoff, C. A. et al. Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy. J. Clin. Invest. 126, 318-334 (2016).
42. Trapani, J. A. & Smyth, M. J. Functional significance of the perforin/granzyme cell death pathway. Nat. Rev. Immunol. 2, 735-747 (2002).
43. Listopad, J. J. et al. Fas expression by tumor stroma is required for cancer eradication. Proc. Natl Acad. Sci. USA 110, 2276-2281 (2013).
44. Watanabe-Fukunaga, R., Brannan, C. I., Copeland, N. G., Jenkins, N. A. & Nagata, S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356, 314-317 (1992).
45. Singer, G. G. & Abbas, A. K. The fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1, 365-371 (1994).
46. Nagata, S. & Suda, T. Fas and Fas ligand: lpr and gld mutations. Immunol. Today 16, 39-43 (1995).
47. Roths, J. B., Murphy, E. D. & Eicher, E. M. A new mutation, gld, that produces lymphoproliferation and autoimmunity in C3H/HeJ mice. J. Exp. Med. 159, 1-20 (1984).
48. Uyttenhove, C., Maryanski, J. & Boon, T. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J. Exp. Med. 157, 1040-1052 (1983).
49. Lethé, B., Van den Eynde, B., Van Pel, A., Corradin, G. & Boon, T. Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide. Eur. J. Immunol. 22, 2283-2288 (1992).
50. Gajewski, T. F., Renauld, J.-C., Van Pel, A. & Boon, T. Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine anti-tumor cytolytic T lymphocytes in vitro. J. Immunol. 154, 5637-5648 (1995).
51. Brändle, D. et al. The shared tumor-specific antigen encoded by mouse gene P1A is a target not only for cytolytic T lymphocytes but also for tumor rejection. Eur. J. Immunol. 28, 4010-4019 (1998).
52. Garcon, N. et al. Non-clinical safety evaluation of repeated intramuscular administration of the AS15 immunostimulant combined with various antigens in rabbits and cynomolgus monkeys. J. Appl. Toxicol. 36, 238-256 (2016).
53. Bilsborough, J. et al. TNF-mediated toxicity after massive induction of specific CD8+T cells following immunization of mice with a tumor-specific peptide. J. Immunol. 169, 3053-3060 (2002).
54. Huijbers, I. J. et al. Minimal tolerance to a tumor antigen encoded by a cancergermline gene. J. Immunol. 188, 111-121 (2012).
55. Van den Eynde, B. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. Journal of Experimental Medicine 173, 1373-1384 (1991)